Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth D Lowenthal

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Children (Basel, Switzerland)|September 28, 2024
Feasibility of Brain Ultrasound Performed by Nurses in the Evaluation of Newborns Who Are HIV Exposed in Utero and Uninfected: A Pilot Study in BotswanaHansel J Otero, Monica Miranda-Schaeubinger, Sara Rae Schenkel, et al.
The Lancet. HIV|March 27, 2024
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding studyElizabeth D Lowenthal, Jennifer Chapman, Rachel Ohrenschall, et al.
The Lancet. HIV|January 17, 2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trialElizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, et al.
The Lancet. HIV|January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm studyAditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
The Lancet. HIV|March 27, 2024
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyAditya H Gaur, Edmund V Capparelli, Katherine Calabrese, et al.
The Lancet. HIV|March 6, 2025
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyCarolyn Bolton Moore, Kristin Baltrusaitis, Brookie M Best, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Children (Basel, Switzerland)|September 28, 2024
Feasibility of Brain Ultrasound Performed by Nurses in the Evaluation of Newborns Who Are HIV Exposed in Utero and Uninfected: A Pilot Study in BotswanaHansel J Otero, Monica Miranda-Schaeubinger, Sara Rae Schenkel, et al.
The Lancet. HIV|March 27, 2024
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding studyElizabeth D Lowenthal, Jennifer Chapman, Rachel Ohrenschall, et al.
The Lancet. HIV|January 17, 2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trialElizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, et al.
The Lancet. HIV|January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm studyAditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
The Lancet. HIV|March 27, 2024
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyAditya H Gaur, Edmund V Capparelli, Katherine Calabrese, et al.
The Lancet. HIV|March 6, 2025
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyCarolyn Bolton Moore, Kristin Baltrusaitis, Brookie M Best, et al.
Pageof 7